# Tirzepatide Dosage Studied in Clinical Trials | Medicinal Tirzepatide

> Tirzepatide dosage protocols from the SURPASS and SURMOUNT phase-3 clinical trials: starting doses, titration schedule, maintenance doses, half-life, and pharmacokinetics — documented from the published record.

## Dose-Escalation Schedule: SURPASS and SURMOUNT Protocols

Tirzepatide dosage studied in clinical trials followed a standardized 4-week step-up protocol specifically designed to reduce gastrointestinal adverse event severity during treatment initiation. The standard schedule in the SURPASS and SURMOUNT programs:

— Starting dose: 2.5 mg once weekly for 4 weeks.
— Step up to 5 mg once weekly for 4 weeks.
— Step up to 10 mg once weekly for 4 weeks.
— Step up to 15 mg once weekly (maximum studied maintenance dose).

Final maintenance doses studied were 5 mg, 10 mg, and 15 mg subcutaneous once weekly. Participants who could not tolerate escalation remained at the last tolerated maintenance dose. Across SURPASS-1 through SURPASS-5, the majority of participants achieved and maintained 15 mg dosing [2, 4, 5].

Onset of action in tirzepatide research. How long does it take for tirzepatide to work? SURPASS-1 showed statistically significant HbA1c reductions by week 8. Weight loss in SURMOUNT-1 became statistically significant versus placebo within 4 weeks of treatment initiation — the first measurable weight effect occurs during the dose-escalation phase [2, 6].

## Tirzepatide Half-Life and Pharmacokinetics

Tirzepatide half life: approximately 5 days (mean 5.4 days from population pharmacokinetic modeling across 19 pooled clinical studies). The terminal half-life of approximately 5 days supports once-weekly subcutaneous administration with low peak-to-trough plasma concentration variability [18].

How long does tirzepatide stay in your system? Terminal half-life approximately 5 days; steady-state plasma concentration reached at approximately 4 weeks of once-weekly dosing (after approximately 4 to 5 doses). Renal clearance is not the primary elimination route — a hepatic impairment pharmacokinetic study (n=32) found AUC and Cmax similar across normal and impaired hepatic function groups, indicating that hepatic metabolism is also not the dominant elimination pathway [18, 19].

Population pharmacokinetic analysis using a two-compartment model with first-order absorption and elimination confirmed consistent pharmacokinetics across demographic subpopulations. No dose adjustment based on age, sex, race, or body weight was identified as clinically necessary [18].

The C20 fatty diacid moiety attached to Lys26 is responsible for albumin binding and the extended half-life. This structural feature enables the once-weekly clinical schedule. For peptide stability context relevant to research samples, see the storage section below.

## Tirzepatide Injection: Subcutaneous Administration in Studies

Tirzepatide injection route in all phase-3 clinical trials: subcutaneous injection, administered once weekly. Approved injection sites in the clinical protocols included the abdomen, thigh, and upper arm. Intravenous administration was studied in dedicated pharmacokinetic studies only.

Injection-site reactions were reported as adverse events in the SURPASS and SURMOUNT programs but at low rates. The most common injection-site findings were mild erythema and transient injection-site pain. No signal of lipodystrophy or clinically significant injection-site pathology was documented in the primary trial publications [14, 15].

Dose units: tirzepatide is dosed in milligrams (mg), not micrograms or international units. The dose-escalation schedule runs from 2.5 mg to a maximum of 15 mg per injection. Each injection is administered on the same day each week; the day of the week may be changed if the minimum interval of 72 hours between injections is maintained [16].

For [tirzepatide dosage studied in clinical trials](/dosage) detail, including the full dose-escalation table and endpoint outcomes by dose arm, refer to the protocol sections on this page. For [tirzepatide side effects](/side-effects) related to injection, including injection-site reactions and GI tolerability data, see the side effects log.

## Tirzepatide Storage and Stability Data

What is the shelf life of compounded tirzepatide? The approved commercial tirzepatide formulation (prefilled injector pen) is stored refrigerated at 2-8°C; the labeling specifies a 24-month shelf life at refrigerated conditions [16]. For lyophilized tirzepatide research peptides, published stability data for acylated GLP-1 peptides with comparable C20 fatty diacid modifications indicate stability at -20°C for 24 months or longer when moisture and light are controlled [18].

Reconstitution and storage protocols for tirzepatide research samples. Standard research protocols for acylated GLP-1 class peptides recommend lyophilized storage at -20°C, reconstitution with sterile bacteriostatic water, and refrigerated single-use or multi-draw storage at 2-8°C protected from light. Reconstituted peptide solution stability in published protocols for structurally related acylated incretin peptides ranges from 28 to 56 days refrigerated [18].

How do you store a tirzepatide compound properly? Lyophilized form: -20°C, moisture-protected, light-protected. Reconstituted solution: 2-8°C refrigerated, protected from light, used within the window specified in the applicable protocol. The C20 fatty diacid backbone is susceptible to standard peptide degradation mechanisms (aggregation, deamidation, oxidation) under unfavorable storage conditions. No tirzepatide-specific reconstituted stability studies were identified in the published peer-reviewed literature at the time this digest was compiled [18].

---

A numbered schematic reading of the tirzepatide trial record — SURPASS and SURMOUNT endpoints indexed, mechanism annotated, no clinical position held.